Jose A. Villadangos

Jose A. Villadangos

Auto-generated profile, based on publicly available information

Jose A. Villadangos

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3052, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2006 in Immunity
Verified
Journal Article
Closed access
RARhys S. Allan
Rhys S. Allan
JWJason Waithman
Jason Waithman
SBSammy Bedoui
Sammy Bedoui
CJClaerwen M. Jones
Claerwen M. Jones
JVJose A. Villadangos
Jose A. Villadangos
FCFrancis R. Carbone
Francis R. Carbone

17 April 1998 in Science
Verified
Journal Article
Closed access
PDF file
TNTerry Nakagawa
Terry Nakagawa
WRWera Roth
Wera Roth
PWPhillip Wong
Phillip Wong
ANAndrew Nelson
Andrew Nelson
AFAndrew Farr
Andrew Farr
ARAlexander Y. Rudensky
Alexander Y. Rudensky
Degradation of invariant chain (Ii) is a critical step in major histocompatibility complex class II–restricted antigen presentation. Cathepsin L was found to be necessary for Ii degradation in cortical thymic epithelial cells (cTECs), but not in bone marrow (BM)–derived antigen-presenting cells (APCs). Consequently, positive selection of CD4 + T cells was reduced. Because different cysteine proteinases are responsible for specific Ii degradation steps in cTECs and BM-derived APCs, the proteolytic environment in cells mediating positive and negative selection may be distinct. The identification of a protease involved in class II presentation in a tissue-specific manner suggests a potential means of manipulating CD4 + T cell responsiveness in vivo.

5 May 2004 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
WHWilliam Ross Heath
William Ross Heath
GBGabrielle T. Belz
Gabrielle T. Belz
GBGeorg M. N. Behrens
Georg M. N. Behrens
CSChristopher M. Smith
Christopher M. Smith
SFSimon P. Forehan
Simon P. Forehan
JVJose A. Villadangos
Jose A. Villadangos

1 July 2007 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
JVJosé A. Villadangos
José A. Villadangos
PSPetra Schnorrer
Petra Schnorrer

7 February 2020 in Science
Verified
Journal Article
Closed access
PDF file
MRMarc Rigau
Marc Rigau
SOSimone Ostrouska
Simone Ostrouska
TFThomas S. Fulford
Thomas S. Fulford
DJDarryl N. Johnson
Darryl N. Johnson
KWKatherine Woods
Katherine Woods
AUAdam P. Uldrich
Adam P. Uldrich
A weird way to recognize phosphoantigens: In contrast to the well-studied αβ T cells, which recognize peptide antigens presented by major histocompatibility complex (MHC) and MHC-like molecules, how γδ T cells recognize antigens remains largely a mystery. One major class of γδ T cells, designated Vγ9Vδ2 + , is activated by small, phosphorylated nonpeptide antigens, or phosphoantigens, produced by microbes and cancer cells. Rigau et al. found that these cells needed the combination of two immunoglobulin superfamily members, butyrophilin 2A1 (BTN2A1) and BTN3A1, on their cell surface to recognize these phosphoantigens. BTN2A1 directly binds the Vγ9 + domain of the T cell receptor (TCR), whereas a second ligand, potentially BTN3A1, binds the Vδ2 and γ-chain regions on the opposite side of the TCR. A better understanding of this unexpected form of T cell antigen recognition should inform and enhance future γδ T cell–mediated immunotherapies. Science , this issue p. eaay5516

1 September 2008 in Immunity
Verified
Journal Article
Closed access
JVJosé A. Villadangos
José A. Villadangos
LYLouise Young
Louise Young